Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) posted its earnings results on Monday. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07, Zacks reports.
Indaptus Therapeutics Trading Down 1.8 %
Shares of INDP traded down $0.03 on Thursday, reaching $1.65. The company’s stock had a trading volume of 1,476 shares, compared to its average volume of 44,805. Indaptus Therapeutics has a twelve month low of $1.56 and a twelve month high of $4.08. The firm has a fifty day moving average of $2.15 and a 200-day moving average of $2.16. The stock has a market capitalization of $14.09 million, a PE ratio of -0.94 and a beta of 1.39.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Indaptus Therapeutics in a research note on Monday, June 17th.
Indaptus Therapeutics Company Profile
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
Recommended Stories
- Five stocks we like better than Indaptus Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Walmart Stock: Buy the Rip or Wait for the Dip?
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 Stocks to Buy for a Soft Landing, If There Is One
- Election Stocks: How Elections Affect the Stock Market
- Why You Shouldn’t Count Out Tencent Music Stock After Earnings
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.